|
| Drug name | Clinical application | Route of administration | Year of approval |
|
| Cytarabine and daunorubicin [26, 67, 68] (CPX-351) | Acute myeloid leukaemia | Intravenous injection | 2017 |
| Irinotecan [69, 70] (Onivyde®) | Pancreatic ductal adenocarcinoma (metastatic) | Intravenous injection | 2015 |
| Doxorubicin [25, 26, 71] (Lipo-dox) | Breast and ovarian cancer, Kaposi’s sarcoma | Intravenous injection | 2013 |
| Vincristine [26, 72, 73] (Marqibo®) | Acute lymphoblastic leukaemia | Intravenous injection | 2012 |
| Exparel [74] | Bupivacaine | Intravenous injection | 2011 |
| Morphine Sulphate [26, 75] (DepoDur®) | Management of pain | Epidural | 2004 |
| Verteporfin [26, 76] (Visudyne®) | Sensitizer in photodynamic therapy for wet macular degeneration | Intravenous injection | 2000 |
| Doxorubicin [26, 77] (Myocet®) | Breast cancer | Intravenous injection | 2000 |
| Cytarabine [26, 78, 79] (DepoCyt®) | Lymphomatous meningitis | Intravenous injection | 1999 |
| Amphotericin B [26, 80, 81] (AmBisome®) | Fungal infections | Intravenous injection | 1997 (USA) and 1990 (Europe) |
| Amphotericin B [26, 82] (Amphotec®) | Aspergillosis (Invasive) | Intravenous injection | 1996 |
| Daunorubicin [26, 83] (DaunoXome®) | Kaposi’s sarcoma | Intravenous injection | 1996 |
| Amphotericin B [26, 84] (Abelcet®) | Aspergillosis | Intravenous injection | 1995 |
| Doxorubicin [26, 85–88] (Doxil®/Caelyx®) | Kaposi’s sarcoma | Intravenous injection | 1995 |
|
